Middle East and Africa Pharmacogenomics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and P

Middle East and Africa Pharmacogenomics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (PCR, Sequencing, Microarray, Gel Electrophoresis, Mass Spectrometry, and Others), Application (Drug Discovery, Oncology, Neurology and Psychiatry, Pain Management, Cardiovascular Diseases, and Others), and End User (Hospitals and Clinics, Biopharmaceutical Companies, CROs and CDMOs, and Others)

The Middle East and Africa pharmacogenomics market is expected to reach US$ 427.68 million by 2028 from US$ 225.72 million in 2021; it is estimated to grow at a CAGR of 9.6% from 2021 to 2028.

The key factors that are driving growth of the market are increasing demand for third generation sequencing along with growing funding for pharmacogenomic research activities. However, the dearth of skilled professionals is expected to restrict the market growth during the forecast period.

The development of newer and better DNA sequencing technologies has led to over a thousand-fold decrease in the cost of sequencing genomes since the launch of the Human Genome Project. The third generation of sequencing underwent development after the next-generation sequencing reached the market. Genomic sequencing technologies have revolutionized mutation detection of genetic diseases in the past few years. The third-generation sequencing (TGS) has gained insight into more genetic disorders due to the single molecular and real-time sequencing technology.

Pacific Biosciences developed new technologies called Single-Molecule Sequencing in Real-Time (SMRT). SMRT is efficient and uses fewer expensive chemicals. Its high sensitivity enables scientists to effectively observe DNA polymerase and watch it make a strand of DNA.

A rise in the demand for third-generation sequencing (TGS) technologies is attributive to the lucrative growth rate of radiation dose management segment. With the emergence of TGS, genome sequencing has become a faster and more reliable method to study genomic variations. SMRT technology has allowed scientists to initiate re-sequencing of the sequenced genome to obtain higher accuracy. Escherichia coli is sequenced to an accuracy of 99.99% by using the SMRT technique.

Third-generation long-range DNA sequencing and mapping technologies are resulting in high-quality genome sequencing. Unlike second-generation sequencing, which produces short reads over a few hundred base-pairs, third-generation single-molecule technologies generate over 10,000 bp reads or map over 100,000 bp molecules.

Middle East and Africa Pharmacogenomics Market Revenue and Forecast to 2028 (US$ Mn)

MIDDLE EAST AND AFRICA PHARMACOGENOMICS MARKET SEGMENTATION

By Technology

Hospitals & Clinics Biopharmaceutical Companies CROs and CDMOs Others By Application

PCRSequencing Microarraygel electrophorosis Mass spectrometry Others By End User

Drugs Discovery Oncology Neurological & Psychiatry Pain Management Cardiovascular Others By Country

UAESaudi Arabia South Africa Rest of Middle East and Africa Company Profiles

Abbott F. HOFFMANN-LA ROCHE LTD.Oxford Nanopore Technologies THERMO FISHER SCIENTIFIC INC.Illumina, Inc.QIAGENAgilent Technologies, Inc.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players and segments in the Middle East and Africa pharmacogenomics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the Middle East and Africa pharmacogenomics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.